

Christine M Lovly

List of Publications by Citations

Source: <https://exaly.com/author-pdf/4139369/christine-m-lovly-publications-by-citations.pdf>

Version: 2024-04-26

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

61
papers

4,783
citations

29
h-index

65
g-index

65
ext. papers

5,901
ext. citations

12
avg, IF

5.62
L-index

#	Paper	IF	Citations
61	ROS1 rearrangements define a unique molecular class of lung cancers. <i>Journal of Clinical Oncology</i> , 2012 , 30, 863-70	2.2	1170
60	Mechanisms of receptor tyrosine kinase activation in cancer. <i>Molecular Cancer</i> , 2018 , 17, 58	42.1	275
59	Inflammatory myofibroblastic tumors harbor multiple potentially actionable kinase fusions. <i>Cancer Discovery</i> , 2014 , 4, 889-95	24.4	250
58	Melanoma-specific MHC-II expression represents a tumour-autonomous phenotype and predicts response to anti-PD-1/PD-L1 therapy. <i>Nature Communications</i> , 2016 , 7, 10582	17.4	248
57	Rationale for co-targeting IGF-1R and ALK in ALK fusion-positive lung cancer. <i>Nature Medicine</i> , 2014 , 20, 1027-34	50.5	191
56	Therapeutic targeting of anaplastic lymphoma kinase in lung cancer: a paradigm for precision cancer medicine. <i>Clinical Cancer Research</i> , 2015 , 21, 2227-35	12.9	188
55	RAS-MAPK dependence underlies a rational polytherapy strategy in EML4-ALK-positive lung cancer. <i>Nature Medicine</i> , 2015 , 21, 1038-47	50.5	177
54	Insights into ALK-driven cancers revealed through development of novel ALK tyrosine kinase inhibitors. <i>Cancer Research</i> , 2011 , 71, 4920-31	10.1	174
53	Frequent mutations in chromatin-remodelling genes in pulmonary carcinoids. <i>Nature Communications</i> , 2014 , 5, 3518	17.4	173
52	Heterogeneous Mechanisms of Primary and Acquired Resistance to Third-Generation EGFR Inhibitors. <i>Clinical Cancer Research</i> , 2016 , 22, 4837-4847	12.9	168
51	Routine multiplex mutational profiling of melanomas enables enrollment in genotype-driven therapeutic trials. <i>PLoS ONE</i> , 2012 , 7, e35309	3.7	153
50	Molecular Pathways: Clinical Applications and Future Direction of Insulin-like Growth Factor-1 Receptor Pathway Blockade. <i>Clinical Cancer Research</i> , 2015 , 21, 4270-7	12.9	109
49	Characteristics of lung cancers harboring NRAS mutations. <i>Clinical Cancer Research</i> , 2013 , 19, 2584-91	12.9	100
48	MAP2K1 (MEK1) Mutations Define a Distinct Subset of Lung Adenocarcinoma Associated with Smoking. <i>Clinical Cancer Research</i> , 2015 , 21, 1935-43	12.9	95
47	Ensartinib (X-396) in ALK-Positive Non-Small Cell Lung Cancer: Results from a First-in-Human Phase I/II, Multicenter Study. <i>Clinical Cancer Research</i> , 2018 , 24, 2771-2779	12.9	86
46	Escaping ALK inhibition: mechanisms of and strategies to overcome resistance. <i>Science Translational Medicine</i> , 2012 , 4, 120ps2	17.5	83
45	Enabling a genetically informed approach to cancer medicine: a retrospective evaluation of the impact of comprehensive tumor profiling using a targeted next-generation sequencing panel. <i>Oncologist</i> , 2014 , 19, 616-22	5.7	80

44	SFK/FAK Signaling Attenuates Osimertinib Efficacy in Both Drug-Sensitive and Drug-Resistant Models of EGFR-Mutant Lung Cancer. <i>Cancer Research</i> , 2017 , 77, 2990-3000	10.1	75
43	Survivorship in Immune Therapy: Assessing Chronic Immune Toxicities, Health Outcomes, and Functional Status among Long-term Ipilimumab Survivors at a Single Referral Center. <i>Cancer Immunology Research</i> , 2015 , 3, 464-9	12.5	71
42	Quantifying Drug Combination Synergy along Potency and Efficacy Axes. <i>Cell Systems</i> , 2019 , 8, 97-108.e16.6	16.6	67
41	An Acquired Gatekeeper Mutation Induces Resistance to Neratinib in a Patient with HER2 Mutant-Driven Breast Cancer. <i>Cancer Discovery</i> , 2017 , 7, 575-585	24.4	66
40	EGFR Fusions as Novel Therapeutic Targets in Lung Cancer. <i>Cancer Discovery</i> , 2016 , 6, 601-11	24.4	65
39	EGFR Kinase Domain Duplication (EGFR-KDD) Is a Novel Oncogenic Driver in Lung Cancer That Is Clinically Responsive to Afatinib. <i>Cancer Discovery</i> , 2015 , 5, 1155-63	24.4	63
38	Longitudinal Cell-Free DNA Analysis in Patients with Small Cell Lung Cancer Reveals Dynamic Insights into Treatment Efficacy and Disease Relapse. <i>Journal of Thoracic Oncology</i> , 2018 , 13, 112-123	8.9	63
37	Expression of ROS1 predicts ROS1 gene rearrangement in inflammatory myofibroblastic tumors. <i>Modern Pathology</i> , 2015 , 28, 732-9	9.8	62
36	Monitoring Therapeutic Response and Resistance: Analysis of Circulating Tumor DNA in Patients With ALK+ Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2019 , 14, 1901-1911	8.9	59
35	On-target Resistance to the Mutant-Selective EGFR Inhibitor Osimertinib Can Develop in an Allele-Specific Manner Dependent on the Original EGFR-Activating Mutation. <i>Clinical Cancer Research</i> , 2019 , 25, 3341-3351	12.9	51
34	ALK Fusion Partners Impact Response to ALK Inhibition: Differential Effects on Sensitivity, Cellular Phenotypes, and Biochemical Properties. <i>Molecular Cancer Research</i> , 2018 , 16, 1724-1736	6.6	48
33	COVID-19 and immune checkpoint inhibitors: initial considerations 2020 , 8,		36
32	Emergence of FGFR3-TACC3 fusions as a potential by-pass resistance mechanism to EGFR tyrosine kinase inhibitors in EGFR mutated NSCLC patients. <i>Lung Cancer</i> , 2017 , 111, 61-64	5.9	29
31	Optimizing the sequence of anti-EGFR-targeted therapy in EGFR-mutant lung cancer. <i>Molecular Cancer Therapeutics</i> , 2015 , 14, 542-52	6.1	26
30	The Path(way) Less Traveled: A Pathway-Oriented Approach to Providing Information about Precision Cancer Medicine on My Cancer Genome. <i>Translational Oncology</i> , 2016 , 9, 163-165	4.9	25
29	amplification is a mechanism of acquired resistance to EGFR inhibitors identified by transposon mutagenesis and clinical genomics. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018 , 115, E6030-E6038	11.5	24
28	BRAF internal deletions and resistance to BRAF/MEK inhibitor therapy. <i>Pigment Cell and Melanoma Research</i> , 2018 , 31, 432-436	4.5	19
27	Improved Prognosis and Increased Tumor-Infiltrating Lymphocytes in Patients Who Have SCLC With Neurologic Paraneoplastic Syndromes. <i>Journal of Thoracic Oncology</i> , 2019 , 14, 1970-1981	8.9	19

26	Tumor Heterogeneity and Therapeutic Resistance. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2016</i> , 35, e585-93	7.1	19
25	Small Cell Lung Cancer Transformation as a Mechanism of Resistance to PD-1 Therapy in KRAS-Mutant Lung Adenocarcinoma: A Report of Two Cases. <i>Journal of Thoracic Oncology, 2019</i> , 14, e45-e48	8.9	19
24	Shades of T790M: Intratumor Heterogeneity in EGFR-Mutant Lung Cancer. <i>Cancer Discovery, 2015</i> , 5, 694-6	24.4	14
23	Combating acquired resistance to tyrosine kinase inhibitors in lung cancer. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2015</i> , e165-73	7.1	13
22	Managing Resistance to EGFR- and ALK-Targeted Therapies. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2017</i> , 37, 607-618	7.1	11
21	Established, emerging and elusive molecular targets in the treatment of lung cancer. <i>Journal of Pathology, 2018</i> , 244, 565-577	9.4	11
20	Strategies for overcoming EGFR resistance in the treatment of advanced-stage NSCLC. <i>Current Treatment Options in Oncology, 2012</i> , 13, 516-26	5.4	11
19	My Cancer Genome: Evaluating an Educational Model to Introduce Patients and Caregivers to Precision Medicine Information. <i>AMIA Summits on Translational Science Proceedings, 2016</i> , 2016, 112-21	1.1	11
18	Cracking the Code of Resistance across Multiple Lines of ALK Inhibitor Therapy in Lung Cancer. <i>Cancer Discovery, 2016</i> , 6, 1084-1086	24.4	10
17	Sequencing Therapy for Genetically Defined Subgroups of Non-Small Cell Lung Cancer. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2018</i> , 38, 726-739	7.1	10
16	Structure-function analysis of oncogenic EGFR Kinase Domain Duplication reveals insights into activation and a potential approach for therapeutic targeting. <i>Nature Communications, 2021</i> , 12, 1382	17.4	8
15	The Pan-Cancer Landscape of Coamplification of the Tyrosine Kinases KIT, KDR, and PDGFRA. <i>Oncologist, 2020</i> , 25, e39-e47	5.7	8
14	Immunotherapy-Mediated Thyroid Dysfunction: Genetic Risk and Impact on Outcomes with PD-1 Blockade in Non-Small Cell Lung Cancer. <i>Clinical Cancer Research, 2021</i> , 27, 5131-5140	12.9	7
13	Somatic Genomic Testing in Patients With Metastatic or Advanced Cancer: ASCO Provisional Clinical Opinion.. <i>Journal of Clinical Oncology, 2022</i> , JCO2102767	2.2	7
12	Stop FRETting the Target: Next-Generation RET Inhibitors Have Arrived. <i>Cancer Discovery, 2018</i> , 8, 797-799	24.4	6
11	Vulnerability of drug-resistant EML4-ALK rearranged lung cancer to transcriptional inhibition. <i>EMBO Molecular Medicine, 2020</i> , 12, e11099	12	5
10	Severity of illness scores at presentation predict ICU admission and mortality in COVID-19. <i>Journal of Emergency and Critical Care Medicine, 2021</i> , 5,	0.6	5
9	Rapidly fatal pneumonitis from immunotherapy and concurrent SARS-CoV-2 infection in a patient with newly diagnosed lung cancer 2020 ,		4

8	Beyond Programmed Death-Ligand 1: B7-H6 Emerges as a Potential Immunotherapy Target in SCLC. <i>Journal of Thoracic Oncology</i> , 2021 , 16, 1211-1223	8.9	4
7	Variable Response to ALK Inhibitors in NSCLC with a Novel MYT1L-ALK Fusion. <i>Journal of Thoracic Oncology</i> , 2019 , 14, e29-e30	8.9	3
6	Vitamin D3 Metabolites Demonstrate Prognostic Value in -Mutant Lung Adenocarcinoma and Can be Deployed to Oppose Acquired Therapeutic Resistance. <i>Cancers</i> , 2020 , 12,	6.6	3
5	Blood-Based Surveillance Monitoring of Circulating Tumor DNA From Patients With SCLC Detects Disease Relapse and Predicts Death in Patients With Limited-Stage Disease. <i>JTO Clinical and Research Reports</i> , 2020 , 1, 100024	1.4	2
4	Forming the Hematology-Oncology Collaborative Videoconferencing (CO-VID) Learning Initiative: Experiential Lessons Learned From a Novel Trainee-Led Multidisciplinary Virtual Learning Platform. <i>JCO Oncology Practice</i> , 2021 , OP2000960	2.3	2
3	A Call to Action: Dismantling Racial Injustices in Preclinical Research and Clinical Care of Black Patients Living with Small Cell Lung Cancer. <i>Cancer Discovery</i> , 2021 , 11, 240-244	24.4	2
2	Circulating Tumor DNA as a Biomarker of Radiographic Tumor Burden in SCLC. <i>JTO Clinical and Research Reports</i> , 2021 , 2, 100110	1.4	0
1	Alpha-T: An innovative decentralized (home-based) phase 2 trial of alectinib in ALK-positive (ALK+) solid tumors in a histology-agnostic setting.. <i>Journal of Clinical Oncology</i> , 2021 , 39, TPS3155-TPS3155	2.2	0